Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) https://validator.w3.org/feed/docs/rss2.html Government Agencies and Related Announcements Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) Antibody-Drug Conjugates (ADCs) – Recent Advances in the Treatment of Solid Tumors Antibody-Drug Conjugates (ADCs): Recent Advances in the Treatment of Solid Tumors Effective CAR T-cell targeting of an MUC1 cleavage product CAR T-cell Immunometabolism: Insights from Patients Chiang Mai University Team Patient Care and Toxicities Management of CAR T-cell in Pediatrics Division of Hematology, Department of Medicine, Faculty of Medicine Thammasat University TTCI Showcases Emerging Immuno-Oncology Talent and Invites Global Community to Thailand for WIC-APAC 2027 Our Team Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy Basic Cancer Immunology for Clinicians Operational Readiness, Safety, and Quality Management for ATMP Clinical Trials in Thailand On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy in glioblastoma models A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma. Stem Cell and Molecular Biology, Center of Excellence in Stem Cell Research and Innovations, Faculty of Medicine, Thammasat University Department of Paediatrics, Faculty of Medicine, Thammasat University Division of Cell Biology, Department of Preclinical Sciences, Faculty of Medicine, Thammasat University AP-SciBio 2027 x WIC APAC 2027 & Thai Immunology Annual Meeting CAR T-cell therapy for paediatric solid tumours: clinical trial development and preclinical modelling Cell Therapy for Solid Cancers: Promise or Overpromise? On-demand GLUT3 expression augments CAR-T cell metabolic fitness and antitumor efficacy in glioblastoma models Affordable Immunotherapy – Opportunities and Challenges Cell Therapy for Solid Cancers – Promise or Overpromise? Member Contents A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement Affordable Immunotherapy: Opportunities and Challenges CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma. TTCI at a glance Mahidol University Team Thammasat University Team Personalized Cancer Vaccines – A New Frontier in Thailand’s Fight Against Cancer Thailand Successfully Hosts Its First WIC APAC Webinar, Drawing Strong Regional Interest in Personalized Cancer Vaccines TTCI Representative Highlights CAR-T Cell Therapy Roadmap at the 74th JSTMCT Annual Meeting in Yokohama IMMUNOLOGY SEMINAR: PEPTIDE CANCER VACCINE EXPERIENCE AT NCI White Paper Pediatric Neuro-Oncology Consortium – Chulalongkorn University Research Forum Scientific Meeting: Medical Applications of Gene Editing and Synthetic Biology Technologies Registration Open: 1st International Scientific Symposium in Hematologic Malignancy (CETH, Chulalongkorn University) NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025 Thai Immunology Annual Meeting 2026 IPOPI | SEAPID | Chulalongkorn | Erasmus MC Meeting 2026 TTCI Webinar “CAR T-cell Immunometabolism, Insights from Patients” International Collaborator Chulalongkorn University Team TTCI Researchers Present and Collaborate at the 29th Annual Meeting of the Japanese Association of Cancer Immunology Khonkaen University Team TTCI to Participate in WIC-APAC 2026